Dennis Langer is Director at MYRIAD GENETICS INC (MYGN). They have made 14 open-market trades across 3 companies since 2007, most recently 2026-08-27.
CIK 0001274225
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $257K since 2025, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| QNRX | BUY | 2025-10-14 | 2025-10-15 | $8.49 | $257K | -26.7% | -16.5% | -39.4% |
| QNRX | SELL | 2024-06-07 | 2024-06-10 | $0.73 | $217 | -15.1% | -15.9% | +33.1% |
| MYGN | SELL | 2021-08-03 | 2021-08-05 | $34.75 | $1.0M | -6.5% | -1.6% | -18.4% |
| DRNA | SELL | 2018-08-15 | 2018-08-17 | $16.00 | $613K | +4.1% | +13.5% | -9.8% |
| MYGN | SELL | 2018-06-06 | 2018-06-08 | $39.35 | $1.6M | -0.3% | -3.7% | +17.7% |
| MYGN | SELL | 2018-06-04 | 2018-06-05 | $39.90 | $335K | -1.0% | -5.6% | +26.5% |
| MYGN | SELL | 2018-06-01 | 2018-06-05 | $39.30 | $2.0M | -1.0% | -5.6% | +26.5% |
| MYGN | SELL | 2018-05-30 | 2018-06-01 | $37.92 | $379K | -1.2% | -4.2% | +25.9% |
| MYGN | SELL | 2018-05-21 | 2018-05-21 | $35.90 | $359K | +10.2% | +9.0% | +17.1% |
| DRNA | SELL | 2016-11-16 | 2016-11-17 | $3.52 | $167K | -31.2% | -30.7% | -25.6% |
| MYGN | SELL | 2012-11-29 | 2012-12-03 | $29.88 | $2.1M | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2009-02-05 | 2009-02-05 | $82.72 | $1.2M | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2008-09-04 | 2008-09-08 | $64.78 | $648K | -0.5% | +0.9% | +0.9% |
| MYGN | SELL | 2007-12-19 | 2007-12-21 | $47.57 | $1.4M | -0.5% | +0.9% | +0.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.